✦ LIBER ✦

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer

✍ Scribed by Sequist, L. V.; Gettinger, S.; Senzer, N. N.; Martins, R. G.; Janne, P. A.; Lilenbaum, R.; Gray, J. E.; Iafrate, A. J.; Katayama, R.; Hafeez, N.; Sweeney, J.; Walker, J. R.; Fritz, C.; Ross, R. W.; Grayzel, D.; Engelman, J. A.; Borger, D. R.; Paez, G.; Natale, R.

Book ID: 118059883
Publisher: American Society of Clinical Oncology
Year: 2010
Tongue: English
Weight: 711 KB
Volume: 28
Category: Article
ISSN: 0732-183X
DOI: 10.1200/jco.2010.30.8338

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multicenter Phase II Trial of the Heat S

Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients With Castration-resistant Prostate Cancer

✍ William K. Oh; Matthew D. Galsky; Walter M. Stadler; Sandy Srinivas; Franklin Ch 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 353 KB

210 EML4-ALK is a sensitive client prote

210 EML4-ALK is a sensitive client protein of Hsp90, and rearrangements of the ALK locus are associated with clinical response to IPI-504 (retaspimycin hydrochloride), a novel Hsp90 chaperone inhibitor, in patients with non-small cell lung cancer

✍ C. Fritz; A. Lim; K. Slocum; C. Tunkey; G. Paez; K. West; R. Ross; E. Normant; L 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Involvement of calcium in the differenti

Involvement of calcium in the differential induction of heat shock protein 70 by heat shock protein 90 inhibitors, geldanamycin and radicicol, in human non-small cell lung cancer H460 cells

✍ Yuo-Sheng Chang; Lee-Chen Lee; Fang-Chun Sun; Chih-Chung Chao; Hua-Wen Fu; Yiu-K 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB 👁 2 views

Both geldanamycin (GA) and radicicol (RA) are HSP90 binding agents that possess antitumour activities. Although the in vitro data indicated that the inhibitory constant of RA is much bigger than that of GA, the in vivo data on drug efficacy might reveal different results. We have recently shown that

The heat shock protein 90 inhibitor, AT1

The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer

✍ Brent Graham; Jayne Curry; Tomoko Smyth; Lynsey Fazal; Ruth Feltell; Isobel Hara 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 376 KB

Antitumor activity of NVP-AUY922, a nove

Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins

✍ Kyung-Hun Lee; Ju-Hee Lee; Sae-Won Han; Seock-Ah Im; Tae-You Kim; Do-Youn Oh; Yu 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 421 KB

O-126 Expression profiling of matrix met

O-126 Expression profiling of matrix metalloproteinases (MMPs) and inhibitors reveals a novel prognostic role for MMP-19 in patients with non-small cell lung cancer

✍ Blackhall, F.; Pintilie, M.; Liu, N.; Pennington, C.; Zhu, C.; Shepherd, F.; Edw 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 296 KB